 The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833TOMM40_301 study NCT01931566 with an adjudicated diagnosis of mild cognitive impairment MCI due to Alzheimers Disease AD. 